Weight-loss drug competition heats up with growing pill market
Published On Sep 17, 2024, 5:32 PM
The competition in the weight-loss drug market is increasing as several companies try to challenge the dominance of Novo Nordisk and Eli Lilly. New oral GLP-1 medications are being developed, potentially offering an alternative to injections. Roche has reported early-stage trial results indicating a 6.1% weight loss with its oral option, while Eli Lilly's candidate has shown a more impressive 14.7% weight loss. Concerns about side effects have emerged, particularly for Roche's pill, impacting its stock performance. Market analysts are skeptical about new entrants unless they significantly differentiate from established products.
Stock Forecasts
LLY
Positive
Eli Lilly remains the leader in this market segment, and its strong trial results for orforglipron may attract positive investor attention. Competition from Roche and others may increase but could potentially hinder their market positions due to efficacy and side effect concerns.
NVO
Positive
Novo's advancements and data suggesting superiority over its own injectable, coupled with other competitors beginning trials, indicate a stronger position than emerging rivals. However, excessive competition may dilute market shares in the long run.
PFE
Negative
Pfizer's recent trial results show competitive weight loss efficacy which could potentially position it well in the market, but like Roche, any potential drawbacks revealed in later trials may negatively impact its stock in the near future.
Related News
On Drug Prices, Harris Pushes for Deeper Cuts While Trump Offers Few Specifics
Oct 8, 2024, 1:07 PM
Both have campaigned for lower prescription costs. Kamala Harris has promised to expand President Biden’s policies. Donald Trump is a wild card.
Stock market today: Dow tumbles 400 points, tech rout leads Nasdaq, S&P 500 lower as 10-year yield tops 4%
Oct 7, 2024, 4:04 PM
Investors have overhauled their views on interest rate cuts after a blowout jobs report, ahead of a week of key inflation data and the start of earnings season.
Stock market today: Dow, S&P 500, Nasdaq slide as 10-year Treasury yield, oil jump
Oct 7, 2024, 2:58 PM
Investors have overhauled their views on interest rate cuts after a blowout jobs report, ahead of a week of key inflation data and the start of earnings season.